Partnering for success
Partnering is key to Avacta’s strategy as we continue to expand our pipeline of innovative treatments for cancer.
Our partnering strategy includes teaming up with pharmaceutical partners to help advance our pipeline products through to market, as well as combining our proprietary platforms with novel warheads to develop next generation cancer therapies.
To explore how we can work together, please contact our Chief Business Officer.
Current partnerships
Tempus
Avacta has entered an artificial intelligence (AI)-focused collaboration with Tempus AI, Inc., a technology company leading the adoption of artificial intelligence to advance precision medicine and patient care. The strategic collaboration provides Avacta access to Tempus’ multimodal datasets comprising primary tumor samples and associated clinical data from over 200,000 patients across a broad range of cancer indications. The collaboration is designed to leverage these data to characterize the deep biology of the tumor microenvironment and fibroblast activation protein (FAP) activity upon which its pre|CISION® technology is based.
AffyXell Therapeutics, a Joint Venture with Daewoong Pharmaceutical Co. Ltd.
Avacta and Daewoong Pharmaceutical Co. Ltd. have established a joint venture in South Korea and entered into a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies incorporating Affimer proteins to enhance the immune-modulatory effects.
LG Chem
South Korea-based LG Chem has the exclusive rights to develop and commercialise, on a worldwide basis, multiple Affimer® therapeutics intended for treatment of patients in the fields of inflammatory disorders and oncology.
POINT Biopharma Inc
Avacta has entered into a license agreement with POINT Biopharma Inc., (taken over by Eli Lilly in late 2023) a clinical-stage pharmaceutical company focused on the development and commercialisation of radioligand therapies for the treatment of cancer, to provide access to Avacta’s pre|CISION® technology for the development of tumor-activated radiopharmaceuticals.